A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| BMS-856 | BMS-856 shows low nanomolar inhibition of 17beta-HSD3 enzymatic activity. It displays inhibition of 17beta-HSD3-mediated cellular conversion of AdT to testosterone and inhibits the 17beta-HSD3-mediated conversion of testosterone necessary to promote AR-dependent transcription. BMS-856 can be used for endocrine therapy of prostate cancer. Uses: Endocrine therapy of prostate cancer. Synonyms: BMS 856; BMS856; UNII-7IQ5DK4G01; 7IQ5DK4G01; 2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-Benzamide. Grades: 98%. CAS No. 863382-83-6. Molecular formula: C29H25ClN2O5. Mole weight: 516.97. |  |
| BMS-863233 HCl | BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication. Check for active clinical trials or closed clinical trials using this agent. Synonyms: BMS-863233; BMS863233; BMS 863233; XL-413; XL413; XL 413. CAS No. 1169562-71-3. Molecular formula: C14H13Cl2N3O2. Mole weight: 289.72. | |
| BMS-890068 | BMS-890068 is an acyclic P1 bi-cyclopropane acylsulfonamidetripeptide that can be used as hepatitis C virus (HCV) NS3 protease inhibitor. Uses: The treatment of hepatitis c. Synonyms: BMS-890068; BMS 890068; BMS890068. | |
| BMS 903452 | G-protein-coupled receptor 119 agonists can stimulate glucose-dependent insulin release by direct action in the pancreas and promote secretion of the incretin GLP-1 by action in the gastrointestinal tract. BMS-903452 is a selective G-protein-coupled receptor 119 (GRP119) agonist and it is efficacious in both acute and chronic in vivo rodent models of diabetes. Till now, no development was reported for the treatment of Type 2 diabetes mellitus using BMS-903452. Uses: Type 2 diabetes mellitus. Synonyms: BMS-903452; BMS 903452; BMS903452; 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one. Grades: 98%. CAS No. 1339944-47-6. Molecular formula: C21H19Cl2FN4O4S. Mole weight: 513.37. | |
| BMS-905 | BMS-905 is a Dual Antagonist of Toll-like Receptors 7 and 8 (TLR7/8). Group: Antagonists. Alternative Names: BMS-905; BMS 905; BMS905. CAS No. 2205846-49-5. Molecular formula: C23H29N3. Mole weight: 347.51. Appearance: Solid powder. Purity: >98%. IUPACName: 2-(2,6-Dimethylpyridin-4-yl)-5-piperidin-4-yl-3-propan-2-yl-1H-indole. Canonical SMILES: CC (C1=C (C2=CC (C)=NC (C)=C2)NC3=C1C=C (C4CCNCC4)C=C3)C. Catalog: ACM2205846495. |  |
| BMS-906024 | BMS-906024, a selective and orally active γ-secretase inhibitor, is a potent inhibitor of pan-Notch receptors with IC50s of 1.6, 0.7, 3.4 and 2.9 nM for Notch-1, -2, -3 and -4 receptors, respectively. It has broad-spectrum antineoplastic activity. Synonyms: (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; NSC-780812; Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-. Grades: ≥98%. CAS No. 1401066-79-2. Molecular formula: C26H26F6N4O3. Mole weight: 556.50. | |
| BMS-908662 | BMS-908662 is a Raf kinase inhibitor with potential antineoplastic activity. It can specifically inhibit RAF kinases, located downstream from RAS in the RAS/RAF/MEK/ERK kinase signaling pathway, which may result in reduced proliferation of tumor cells. Phase I for the treatment of Colorectal cancer and Malignant melanoma was discontinued. Uses: Colorectal cancer; malignant melanoma. Synonyms: methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindolin-1-yl)-1H-benzo[d]imidazol-2-yl)carbamate;BMS908662; BMS-908662; BMS 908662; XL281; XL 281; XL-281. Grades: 98%. CAS No. 870603-16-0. Molecular formula: C24H19ClN4O4. Mole weight: 462.89. | |
| BMS 911543 | BMS 911543. Group: Biochemicals. Alternative Names: N,N-Dicyclopropyl-4-[(1,5-dimethyl-1H-pyrazol-3-yl)amino]-6-ethyl-1,6-dihydro-1-methyl-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide. Grades: Highly Purified. CAS No. 1271022-90-2. Pack Sizes: 5mg. Molecular Formula: C23H28N8O, Molecular Weight: 432.52. US Biological Life Sciences. |  Worldwide |
| BMS-911543 | BMS-911543 is an orally available JAK inhibitor with selectivity for JAK2. It inhibts JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. Synonyms: BMS 911543. Grades: >98%. CAS No. 1271022-90-2. Molecular formula: C23H28N8O. Mole weight: 432.532. | |
| BMS-911543 | BMS-911543 is a selective JAK2 inhibitor, with IC 50 s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 ( IC 50 , 75, 360, 66 nM, respectively). Uses: Scientific research. Group: Signaling pathways. CAS No. 1271022-90-2. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15270. |  |
| BMS-919373 | This active molecular is a Kv1.5 potassium channel inhibitor originated by Bristol-Myers Squibb. Treatment for paroxysmal atrial fibrillation is in Phase II clinical trials. Treatment for Acute coronary syndromes and Atrial fibrillation is in Phase I clinical trials. Synonyms: BMS 919373; BMS919373; 3-Pyridinesulfonamide, 5-[5-phenyl-4-[(2-pyridinylmethyl)amino]-2-quinazolinyl]-; 5-[5-Phenyl-4-[(2-pyridinylmethyl)amino]-2-quinazolinyl]-3-pyridinesulfonamide; 5-[5-phenyl-4-[[(pyridin-2-yl)methyl]amino]quinazolin-2-yl]pyridine-3-sulfonamide. Grades: 98%. CAS No. 1272353-82-8. Molecular formula: C25H20N6O2S. Mole weight: 468.54. | |
| BMS-935177 | BMS-935177 is a potent and selective reversible inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 3 nM and demonstrates good kinase selectivity. It is more potent against BTK than other kinase, including the other Tec family kinases (TEC, BMX, ITK, and TXK) over which the compound is between 5- and 67-fold selective. BMS-935177 inhibited calcium flux in human Ramos B cells with IC50 of 27 nM and inhibited CD69 surface expression in peripheral B cells stimulated with anti-IgM and anti-IgG. Synonyms: BMS-935177; BMS935177. Grades: ≥98%. CAS No. 1231889-53-4. Molecular formula: C31H26N4O3. Mole weight: 502.56. | |
| BMS-936559 | Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. Synonyms: MDX1105; BMS936559; MDX 1105; BMS 936559; MDX-1105; BMS-936559; Anti PD L1; PD-L1 inhibitor -Bristol-Myers Squibb. | |
| BMS-955176 | BMS-955176 is the second generation HIV-1 maturation inhibitor. Synonyms: BMS-955176 free base|BMS-955176|UNII-4CA9IAU7RJ|4CA9IAU7RJ|GSK3532795|139 2312-45-6|1392312-45-6 (free base) |GSK-3532795|CHEMBL3827379|SCHEMBL1269786 2|BMS-955176 TFA|EX-A3677|BDBM50450015|BMS955176|DB15193 |2097784-79-5|AC-36687|HY-112714|CS-0062829|4 ( (1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR) 3a- ( (2- (1, 1-Dioxidothiomorpholino) ethyl ) amino )-5a, 5b, 8, 8, 11a-penta methyl -1- (prop-1-en-2-yl ) -2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13boctad eca hydro1Hcyclopenta [a] chrysen-9-yl ) benzoic Acid|4-((1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR)-3a-((2-(1, 1-dioxido-4-thiomorpholinyl)ethyl)amino)-1-isopropenyl-5a, 5b, 8, 8, 11a-pentamethyl-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid|4-((1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR)-3a-((2-(1, 1-dioxidothiomorpholino)ethyl)amino)-5a, 5b, 8, 8, 11a-pentamethyl-1-(prop-1-en-2-yl)-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid|4-[(1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR)-3a-[[2-(1, 1-dioxido-4-thiomorpholinyl)ethyl]amino]-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13b-octadecahydro-5a, 5b, 8, 8, 11a-pentamethyl-1-(1-methylethenyl)-1H-cyclopenta[a]chrysen-9-yl]-benzoic acid|4-[(1R, 3aS, 5aR, 5bR. .. Grades: ≥98% (HPLC). CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691. | |
| BMS-955176 free base | GSK3532795, also known as BMS-955176, is a potent, orally active, second-generation HIV-1 maturation inhibitor (MI) that advanced through phase IIb clinical trials. GSK3532795 combines broad coverage of polymorphic viruses (EC50 <15 nM toward a panel of common polymorphisms representative of 96.5% HIV-1 subtype B virus) with a favorable pharmacokinetic profile in preclinical species. Group: Inhibitors. Alternative Names: GSK3532795; GSK-3532795; GSK 3532795; BMS-955176; BMS 955176; BMS955176. CAS No. 1392312-45-6. Molecular formula: C42H62N2O4S. Mole weight: 691.03. Appearance: Solid powder. Purity:>98%. IUPACName: 4 - ((1R, 3aS, 5aR, 5bR, 7aR, 11aS, 11bR, 13aR, 13bR) - 3a-((2-(1, 1-Dioxidothiomorpholino)ethyl)amino)-5a, 5b, 8, 8, 11a-pentamethyl-1-(prop-1-en-2-yl)-2, 3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 11, 11a, 11b, 12, 13, 13a, 13boctadecahydro - 1H - cyclopenta[a]chrysen-9-yl)benzoic Acid. Canonical SMILES: O=C (O)C1=CC=C (C2=CC[C@@]3 (C)[C@@] (C2 (C)C) ([H])CC[C@@]4 (C)[C@]5 (C)CC[C@] (CC[C@H]6C (C)=C) (NCCN (CC7)CCS7 (=O)=O)[C@@]6 ([H])[C@@]5 ([H])CC[C@]34[H])C=C1. Catalog: ACM1392312456. | |
| BMS-955176 TFA | BMS-955176 TFA is the second generation HIV-1 maturation inhibitor. Synonyms: MS-955176 TFA. CAS No. 2097784-79-5. Molecular formula: C44H63F3N2O6S. Mole weight: 805.05. | |
| BMS-955829 | BMS-955829 shows excellent Metabotropic glutamate receptor 5 (mGluR5) binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype. BMS-955829 is a potent mGluR5 Positive allosteric modulator (PAM) (EC50 = 2.6 ± 1.0 nM; n=6), devoid of inherent mGluR5 agonist activity (EC50 > 30μM). It may become a new drug candidate for the treatment of schizophrenia. Uses: Schizophrenia. Synonyms: BMS-955829; BMS 955829; BMS955829. (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. Grades: 98%. CAS No. 1375751-08-8. Molecular formula: C22H14F2N2O2. Mole weight: 376.36. | |
| BMS 961 | BMS 961 is a potent and selective retinoic acid receptor gamma (RARγ) agonist with an IC50 value of 30 nM. Synonyms: BMS961; BMS-961; 3-Fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino]-benzoic acid; Benzoic acid, 3-fluoro-4-[[2-hydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)acetyl]amino]-. Grades: ≥97% by HPLC. CAS No. 185629-22-5. Molecular formula: C23H26FNO4. Mole weight: 399.45. | |
| BMS 961 | BMS 961. Group: Biochemicals. Grades: Purified. CAS No. 185629-22-5. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS-978587 | BMS-978587 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 ( IDO-1 ) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: IDO-IN-4. CAS No. 1629125-65-0. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18769. | |
| BMS-983970 | BMS-983970 is an oral pan-Notch inhibitor for the treatment of cancer. Synonyms: BMS-983970; BMS 983970; BMS983970. Grades: >98%. CAS No. 1584713-87-0. Molecular formula: C26H26F4N4O3. Mole weight: 518.5. | |
| BMS-986016 | | |
| BMS 986020 | BMS 986020 is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist with an IC50 value less than 300 nM for human LPA1 expressing CHO cells. It inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS 986020 is used for the treatment of idiopathic pulmonary fibrosis (IPF). Synonyms: BMS-986020; BMS986020. Grades: ≥98%. CAS No. 1257213-50-5. Molecular formula: C29H26N2O5. Mole weight: 482.5. | |
| BMS-986094 | BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC 50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INX-08189. CAS No. 1234490-83-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13337. | |
| BMS-986120 | BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vascular occlusion. It was just completed a Phase I trail in in Thrombosis. Synonyms: BMS-986120; BMS 986120; BMS986120; 4-(4-(((6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)benzofuran-4-yl)oxy)methyl)-5-methylthiazol-2-yl)morpholine. Grades: 98%. CAS No. 1478712-37-6. Molecular formula: C23H23N5O5S2. Mole weight: 513.59. | |
| BMS-986120 | BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 ( PAR4 ) antagonist, with IC 50 s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1478712-37-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19837. | |
| BMS 986122 | BMS 986122 is a positive allosteric modulator of the μ-Opioid receptor. It significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells. BMS 986122 potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant μ-opioid receptors with EC50 of 8.9 μM. It also enhances [35S]GTPγ binding stimulated by the μ-opioid agonist DAMGO by 7- and 4.5-fold in C6μ glioma cell membranes. Synonyms: BMS-986122; BMS986122; 2-(3-bromo-4-methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine. Grades: ≥98%. CAS No. 313669-88-4. Molecular formula: C16H15BrClNO3S2. Mole weight: 448.8. | |
| BMS-986141 | BMS-986141 is a potential medication under the clinical trial that evaluates the pharmacokinetics of BMS-986141 in participants with hepatic impairment compared to healthy participants. Synonyms: Unii-W530irz40G. CAS No. 1478711-48-6. Molecular formula: C27H23N5O5S2. Mole weight: 561.6. | |
| BMS-986142 | BMS-986142 is a potent and highly selective reversible small molecule inhibitor of BTK with an IC50 of 0.5 nM. In a panel of 384 kinases, only five kinases were inhibited by BMS-986142 with less than 100-fold selectivity for BTK (TEC, ITK, BLK, TXK and BMX). Group: Fluorinated apis. CAS No. 1643368-58-4. Molecular formula: C32H30F2N4O4. Mole weight: 572.62. Appearance: White to off-white solid powder. Purity: >98%. IUPACName: (7S)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5H-carbazole-1-carboxamide. Catalog: OFC1643368584. | |
| BMS-986142 | Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase. It is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling. BMS-986142 is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM. It potently inhibits BCR-stimulated expression of CD69 on B cells in human whole blood with IC50 of 90 nM. Synonyms: BMS-986142; BMS986142. Grades: ≥98%. CAS No. 1643368-58-4. Molecular formula: C32H30F2N4O4. Mole weight: 572.60. | |
| BMS-986158 | BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins with potential antineoplastic activity. Synonyms: 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol; BMS-986158; BMS 986158; BMS986158. CAS No. 1800340-40-2. Molecular formula: C30H33N5O2. Mole weight: 495.62. | |
| BMS-986158 | BMS-986158 is a potent BET inhibitor with IC 50 s of 6.6 and 5?nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1800340-40-2. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg. Product ID: HY-101567. | |
| BMS-986165 | BMS-986165 is a potent and selective TYK2 inhibitor that blocks signal transduction of IL-23, IL-12, and type I IFNs. It binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM), and is highly selective against a panel of 265 kinases and pseudokinases. BMS-986165 is under a phase III clinical trial for the treatment of Psoriasis. Synonyms: Tyk2-IN-4; BMS 986165; BMS986165. Grades: 98%. CAS No. 1609392-27-9. Molecular formula: C20H19D3N8O3. Mole weight: 425.47. | |
| BMS-986176 | BMS-986176, also known as LX9211, is a highly selective, CNS penetrant, potent AAK1 inhibitor from a novel class of bi(hetero)aryl ethers. BMS-986176/LX9211 (34) showed excellent efficacy in two rodent neuropathic pain models and excellent central nervous system (CNS) penetration and target engagement at the spinal cord with an average brain to plasma ratio of 20 in rat. The compound exhibited favorable physicochemical and pharmacokinetic properties, had an acceptable preclinical toxicity profile, and was chosen for clinical trials. Group: Inhibitors. Alternative Names: LX9211; LX-9211; LX 9211; BMS-986176; BMS 986176; BMS986176. CAS No. 1815613-42-3. Molecular formula: C19H23F4N3O. Mole weight: 385.41. Appearance: Solid powder. Purity: >98%. IUPACName: ( S)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amin. Canonical SMILES: CC (C)C[C@@] (N) (C)COC1=C (C (F)F)N=C (C2=CC (C (F)F)=NC=C2)C=C1. Catalog: ACM1815613423. | |
| BMS 986187 | BMS 986187 is a potent and selective δ-opioid receptor positive allosteric modulator (EC50 = 30 nM) exhibiting 100-fold selectivity for δ over μ-opioid receptor. Synonyms: BMS 986187; BMS986187; BMS-986187; 3,4,5,6,7,9-Hexahydro-3,3,6,6-tetramethyl-9-[4-[(2-methylphenyl)methoxy]phenyl]-1H-xanthene-1,8(2H)-dione. Grades: ≥98% by HPLC. CAS No. 684238-37-7. Molecular formula: C31H34O4. Mole weight: 470.61. | |
| BMS-986187 | BMS-986187 is an δ-opioid receptor -selective positive allosteric modulator (PAM) with an EC 50 of 0.03 μM and a pK B of 6.02 (~1 μM). BMS-986187 has no observable PAM activity at the μ-receptor (EC 50 =3 μM) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 684238-37-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120613. | |
| BMS 986188 | BMS 986188 is a novel potent and selective positive allosteric modulator of the delta-opioid receptor. It is selective for δ- over μ-opioid receptors with EC50 of 10 μM in the presence of leu-enkephalin and the μ-opioid receptor agonist endomorphin 1, respectively. Synonyms: MS-986188; BMS 986188. Grades: ≥98%. CAS No. 1776115-10-6. Molecular formula: C30H31BrO4. Mole weight: 535.5. | |
| BMS-986195 | BMS-986195 is a Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 0.1 nM. Synonyms: Branebrutinib; BMS 986195; BMS986195. Grades: ≥98% by HPLC. CAS No. 1912445-55-6. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS986195 R-isomer | An R isomer of BMS-986195, a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). Synonyms: (R)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide; (R)-Branebrutinib; (R)-BMS-986195. CAS No. 1912445-70-5. Molecular formula: C20H23FN4O2. Mole weight: 370.42. | |
| BMS-986205 | BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. It is undergoing a phase I/II clinical trial for the bladder and cervical cancer therapy in combination with nivolumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. Uses: Drug combination with nivolumab. Synonyms: BMS-986205; BMS 986205; BMS986205; (2R)-N-(4-chlorophenyl)-2-[4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide. CAS No. 1923833-60-6. Molecular formula: C24H24ClFN2O. Mole weight: 410.917. | |
| BMS-986278 | BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K b s of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2170126-74-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139853. | |
| BMS-986299 | BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC 50 of 1.28 μM. (patent WO2018152396A1). Uses: Scientific research. Group: Signaling pathways. CAS No. 2242952-69-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139396. | |
| BMS-986365 | BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor ( AR ) PROTAC degrader, capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor ( AR ), as well as various AR mutants. BMS-986365 shows significant in vivo potency, degrading AR , inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. (Blue: HY-W247437; Black: linker (HY-W126831); Pink: HY-168697) [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CC-94676. CAS No. 2446928-30-7. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-158101. | |
| BMS-986397 | BMS-986397. Uses: Scientific research. Group: Signaling pathways. CAS No. 2564486-44-6. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-159646. | |
| BMS CCR2 22 | BMS CCR2 22. Group: Biochemicals. Grades: Purified. CAS No. 445479-97-0. Pack Sizes: 1mg, 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS CCR2 22 | BMS CCR2 22 is a potent CCR2 antagonist. Synonyms: N-[2-[[2-[ (4-methylsulfanylbenzoyl) amino]cyclohexyl]amino]-2-oxoethyl]-2- (propan-2-ylcarbamoylamino) -5- (trifluoromethyl) benzamide. CAS No. 445479-97-0. Molecular formula: C28H34F3N5O4S. Mole weight: 593.66. | |
| BMT-1438 | BMT-1438 is a selective inhibitor of Janus kinase (JAK) family with less side effcts which is potentially used for the treatment of rheumatoid arthritis and other autoimmune diseases. It has a preference for JAK1 and JAK3. BMT-1438 showed excellent effect both in vitro and in a collagen-induced arthritis mouse model. Uses: The potential treatment of rheumatoid arthritis and other autoimmune diseases. Synonyms: BMT-1438; BMT 1438; BMT1438. | |
| BMT-145027 | BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy. Synonyms: BMT-145027; BMT 145027; BMT145027; 3-[4-chloro-3-(trifluoromethyl)phenyl]-4-cyclopropyl-6-phenyl-2H-pyrazolo[3,4-b]pyridine-5-carbonitrile. CAS No. 2018282-44-3. Molecular formula: C23H14ClF3N4. Mole weight: 438.83. | |
| Bmt I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (Hind III-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 20-fold overdigestion with enzyme about 95% of the dna fragments can be ligated and recut. Group: Restriction Enzymes. Purity: 1000U; 5000U. GCTAG↑C C↓GATCG. Activity: 20000u.a./ml. Appearance: 10 X SE-buffer W. Storage: -20°C. Form: Liquid. Source: An E.coli strain that carries the cloned Bmt I gene from Bacillus megaterium S2. Pack: 10 mM Tris-HCl (pH 7.5); 200 mM NaCl; 0.1 mM EDTA; 1 mM DTT; 200 μg/ml BSA; 50% glycerol. Cat No: ET-1036RE. |  |
| Bmu I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA (HindIII-digest) in 1 hour at 37°C in a total reaction volume of 50 μl. Applications: After 2-fold overdigestion with enzyme about 75% of the dna fragments can be ligated and 95% may be recut. Group: Restriction Enzymes. Purity: 50U; 250U. ACTGGG(N)5↑ TGACCC(N)4&darr. Activity: 500-1000u.a./ml. Appearance: 10 X SE-buffer Y. Storage: -20°C. Form: Liquid. Source: Bacillus megaterium S87. Pack: 10 mM Tris-HCl (pH 7.5); 250 mM NaCl; 0.1 mM EDTA; 7 mM 2-mercaptoethanol; 50% glycerol. Cat No: ET-1037RE. | |
| BMVC | BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC 50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC 50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 627810-06-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135775. | |
| BMV Gag-(7-25) | It is a cell penetrating peptide. Synonyms: H-Lys-Met-Thr-Arg-Ala-Gln-Arg-Arg-Ala-Ala-Ala-Arg-Arg-Asn-Arg-Trp-Thr-Ala-Arg-OH; L-lysyl-L-methionyl-L-threonyl-L-arginyl-L-alanyl-L-glutaminyl-L-arginyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-arginyl-L-asparagyl-L-arginyl-L-tryptophyl-L-threonyl-L-alanyl-L-arginine. Grades: ≥95%. Molecular formula: C96H170N44O24S. Mole weight: 2356.76. | |
| BMX-IN-1 | BMX-IN-1 selectively and irreversibly inhibits BMX (IC50=8nM) that is significant for ischemia-mediated arteriogenesis and lymphangiogenesis regulation. It also inhibits the proliferation of RV-1 (GI50s=2.54μM), DU-145 (GI50s=4.38μM), PC-3 (GI50s=5.37nM). Synonyms: N-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamideBMX-IN-1; BMX-IN1; BMX-IN 1.1431525-23-3GTPL9269SCHEMBL17052523BDBM102620CS-1295; HY-80002; W-6056; CS 1295; HY 80002; W 6056; CS1295; HY80002; W6056Example 1-14 [ WO2014063054]N-[5-[9-[4-(methanesulfonamido)phenyl]. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.59. | |
| BMX-IN-1 | A cell-permeable tricyclic quinoline-acrylamide compound that potently inhibits BMX and BTK kinase activity (IC50 = 8 and 10.4nM, respectively) by covalently targeting ATP-binding site cysteine, while being less potent against TEC family kinases TEC, JAK3, BLK with the same conserved cysteine (IC50 = 175, 377, and 653nM, respectively). Only PI 3-K gamma/PIK3CG, SBK1, PIP5K2C (by ≥94% at 1uM), and TXK (by 75% at 1uM) are significantly inhibited by BMX-IN-1 in a selectivity profiling against 437 other kinase constructs. Potently inhibits the proliferation of TEL-BMX transformed Ba/F3 Ba/F3 (GI50 = 25nM), while being much less effective against TEL-BLK, TEL-JAK1, TEL-JAK2, TEL-JAK3, or TEL-TYK2E957D transformed Ba/F3 (GI50 = ≥3.64uM) or a panel of 5 prostate cancer cell lines (GI50 ≥2.46uM). Group: Biochemicals. Alternative Names: N- (2-Methyl-5- (9- (4- (methylsulfonamido) phenyl) -2-oxobenzo[h][1, 6]naphthyridin-1 (2H) -yl) phenyl) acrylamide, BMX/BTK Inhibitor, Bruton's Tyrosine Kinase Inhibitor IV, BLK Inhibitor I, BMX Inhibitor I, JAK3 Inhibitor XIII, PI 3-K Inhibitor XX, PIP5K2C Inhibitor I, SBK1 Inhibitor I, TEC Inhibitor I, TXK Inhibitor I. Grades: Highly Purified. CAS No. 1431525-23-4. Pack Sizes: 10mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| BMX-IN-1 | BMX-IN-1 is a selective irreversible BMX inhibitor for prostate cancer. BMX-IN-1 can covalently modifies Cys496. BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concentrations but requires single digit micromolar concentrations to inhibit the proliferation of prostate cancer cell lines. MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells. Group: Inhibitors. Alternative Names: BMX-IN-1; BMX-IN1; BMX-IN 1. CAS No. 1431525-23-3. Molecular formula: C29H24N4O4S. Mole weight: 524.6. Appearance: Solid powder. Purity: >98%. IUPACName: N-[5-[9-[4- (methanesulfonamido)phenyl]-2-oxobenzo[h][1, 6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide. Canonical SMILES: C=CC (NC1=CC (N2C (C=CC3=C2C4=CC (C5=CC=C (NS (=O) (C)=O)C=C5)=CC=C4N=C3)=O)=CC=C1C)=O. Catalog: ACM1431525233. | |
| BMY 14802 | BMY 14802 is a sigma-1 receptor ( σ1R ) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 105565-56-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153091. | |
| Bmy 14802 hydrochloride | Heterocyclic Organic Compound. Alternative Names: BMY 14802 hydrochloride;alpha-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride. CAS No. 105565-55-7. Molecular formula: C18H22F2N4O.HCl. Mole weight: 384.85. Purity: >99 %. Catalog: ACM105565557. | |
| BMY 14802 hydrochloride | BMY 14802 hydrochloride is a potent sigma receptor antagonist (IC50 = 112 nM) with weak affinity for 5-HT1A and α1 receptors. BMY 14802 is potentially used as an atypical antipsychotic agent for schizophrenia treatment. Uses: Potential atypical antipsychotic agent. Synonyms: BMY 14802 hydrochloride; BMS-181100 hydrochloride; BMY14802 hydrochloride; BMS181100 hydrochloride; BMY-14802 hydrochloride; BMS 181100 hydrochloride; BMY 14802 HCl; α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride. Grades: ≥98% by HPLC. CAS No. 105565-55-7. Molecular formula: C18H22F2N4O.HCl. Mole weight: 384.86. | |
| BMY-14802 hydrochloride | BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC 50 of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BMY-14802-1; BMS 181100 hydrochloride. CAS No. 105565-55-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108509. | |
| BMY 20366 | Heterocyclic Organic Compound. CAS No. 106872-71-3. Catalog: ACM106872713. | |
| BMY-28160 | BMY-28160 is an ester peptide antibiotic produced by Bacillus circulans H913-B4. It has anti-gram-positive bacteria, negative bacteria, anaerobic bacteria and fungi activity. Synonyms: Polypeptin A, 2-L-valine-9-L-serine-. CAS No. 94593-78-9. Molecular formula: C53H90N12O12. Mole weight: 1087.35. | |
| BMY-28190 | BMY-28190 is an antiviral antibiotic produced by Streptoalloteichus hindustanus E46594, which is a complex composed of D-a.Z-diaminobutyric acid. It has weak anti-gram-positive and negative bacteria activity, but has a strong inhibitory effect on type 1 herpes simplex virus (HSV-1), with IC50 of 2.8 μg/mL. CAS No. 117153-91-0. Molecular formula: (C4H8N2O)n. | |
| Bmy-40124 | Heterocyclic Organic Compound. CAS No. 116163-01-0. Catalog: ACM116163010. | |
| Bmy 42393 | BMY-42393 is a selective platelet aggregation inhibitor. It is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation with IC50 value range from 0.3 to 2.0 mM. BMY-42393 can stimulate platelet adenylate cyclase with EC50 value of 25 nM. BMY 42393 can also inhibit thrombin-induced elevation of intracellular free calcium. Research for the treatment of Hyperlipidaemia was discontinued. Uses: Hyperlipidaemia. Synonyms: BMY-42393; BMY 42393; BMY42393. SCHEMBL675089; AC1L304B; CHEMBL117835;2-[3-[2-(4,5-diphenyl-1,3-oxazol-2-yl)ethyl]phenoxy]acetic acid. Grades: 98%. CAS No. 136451-58-6. Molecular formula: C25H21NO4. Mole weight: 399.45. | |
| BMY 45778 | BMY 45778 is a non-prostanoid prostacyclin mimetic that acts as a partial agonist of IP1 prostacyclin receptors. It inhibits platelet aggregation in vitro (IC50 = 27-35 nM). Synonyms: BMY 45778; BMY45778; BMY-45778. [3-(4,5-Diphenyl[2,4'-bioxazol]-5'-yl)phenoxy]acetic acid. Grades: ≥99% by HPLC. CAS No. 152575-66-1. Molecular formula: C26H18N2O5. Mole weight: 438.44. | |
| BMY 7378 | BMY 7378 is a selective antagonist of α 1D -adrenoceptor (α 1D -AR). BMY 7378 binds to membranes expressing the cloned rat α 1D -AR with a >100-fold higher affinity ( K i =2 nM) than binding to either the cloned rat α 1A -AR (K i =800 nM) or the hamster α 1B -AR ( K i =600 nM). BMY 7378 is a 5-HT 1A receptor partial agonist [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 21102-95-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg. Product ID: HY-100554. | |
| BMY 7378 | BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. Uses: Adrenergic alpha-antagonists. Synonyms: BMY7378; BMY-7378; 1,1-Cyclopentanediacetimide, N-(2-(4-(o-methoxyphenyl)-1-piperazinyl)ethyl)-, dihydrochloride; N-(2-(4-(o-Methoxyphenyl)-1-piperazinyl)ethyl)-1,1-cyclopentanediacetimide dihydrochloride. Grades: >98%. CAS No. 21102-95-4. Molecular formula: C22H33Cl2N3O3. Mole weight: 458.42. | |
| BMY 7378 dihydrochloride | BMY 7378 dihydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 21102-95-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BN-104 | BN-104 (BNM-1192) is an effective selective brain membrane protein inhibitor with oral activity, and it's also a Menin inhibitor, it can block the Menin-MLL interaction and leads to the degradation of Menin protein. BN-104 is a weak hERG inhibitor, with an IC 50 greater than 100 μM. BN-104 has anti-tumor activity and can be used in cancer research, such as for acute myeloid leukemia [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: BNM-1192; Menin-MLL inhibitor 27. CAS No. 2938995-50-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153714. | |
| BN-227F | BN-227F is an antibiotic produced by Pseudomonas sp. BN-227. It has anti-gram-positive and negative bacteria activity. Synonyms: Antibiotic BN 227F. CAS No. 72907-24-5. Molecular formula: C21H24FeN3O9. Mole weight: 518.27. | |
Our database is helping our users find suppliers everyday.
